INSIGHTS ON CLINICAL TRIAL PARTNERING

• Successful Partnership Advances AML Program To Phase II/III

  See how strong collaboration rescued a stalled AML study, proved a safer approach to a proven drug class, and turned a Phase I/II partnership into a global Phase II/III trial.

• Nectin 4 Biomarker Testing For Oncology Clinical Programs

  No validated test existed for a key tumor biomarker. See how a tissue-staining assay was built, validated, and scaled to select the right patients for a cancer trial. 

• Enabling You And Your Sites To Trial Wisely

  Clinical trial sites are asked to do more with less, and these examples show how a connected approach to site enablement drives measurable efficiencies and strengthens relationships.

• Biopharma Giant Streamlines Infrastructure With Proprietary Software

  Archiving legacy QMS systems into a centralized platform reduced costs, simplified access, and improved efficiency for a global diagnostics company undergoing quality process harmonization.

• Mastering Precision Oncology Start-Up: Reducing Screening Delays

  3/30/2026

  Biomarker-driven trials create intricate screening hurdles. Explore creative, practical ways to accelerate start‑up, boost enrollment, and power precision oncology studies forward with greater speed.

• Clinical Trial Data Storage Requirements: What Sponsors Need To Know

  7/15/2026

  Managing growing clinical trial data requires the right storage strategy. Learn how to balance scalability, security, compliance, and operational efficiency.

• Central Laboratory Solutions

  9/29/2026

  Global clinical trials need central laboratory networks able to scale across countries while keeping biomarker and biospecimen data consistent from one study site to the next.

• Start Fast, Scale Seamlessly: Why A Different Oncology Model Was Needed

  5/1/2026

  Oncology programs don’t lose momentum because the science fails, but because execution fractures as complexity grows. Learn how continuity-first operating models help sponsors move faster.

• Expand Bandwidth With A Trusted Regulatory Writing Partner

  9/18/2025

  Find out how a mid-size biotech lacking the bandwidth, expertise, and resources to independently handle its regulatory writing requirements overcame this challenge.